Ultra rapid lispro (URLi) shows accelerated pharmacokinetics and greater reduction in postprandial glucose versus Humalog® in patients with type 1 diabetes mellitus in a randomized, double‐blind meal test early‐phase study

AIM: To compare the pharmacokinetics (PK), glucodynamics (GD), and tolerability following single and multiple daily subcutaneous (SC) doses of ultra rapid lispro (URLi) and Humalog® in patients with type 1 diabetes mellitus (T1D). MATERIALS AND METHODS: This was a two‐part, randomized, double‐blind,...

Descripción completa

Detalles Bibliográficos
Autores principales: Kazda, Christof, Leohr, Jennifer, Liu, Rong, Reddy, Shobha, Dellva, Mary Anne, Loh, Mei Teng, Hardy, Thomas, Plum‐Mörschel, Leona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9297852/
https://www.ncbi.nlm.nih.gov/pubmed/34595812
http://dx.doi.org/10.1111/dom.14563

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9297852/
https://www.ncbi.nlm.nih.gov/pubmed/34595812
http://dx.doi.org/10.1111/dom.14563

Ejemplares similares